Loading
Cetrelimab is an experimental investigational agent whose form is not stated in the registry from Janssen Research & Development in phase 3 trials for bladder & urothelial cancer, prostate cancer and non-small-cell lung cancer, with its target not yet stated publicly.
Cetrelimab (JNJ-63723283) is an investigational agent whose form is not stated in the registry developed by Janssen Research & Development. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: Participants will receive intravenous Cetrelimab. It is the investigational product in 6 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT04658862 (A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder) and NCT05714202 (A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)), in bladder & urothelial cancer, prostate cancer and non-small-cell lung cancer. The largest, NCT05714202, plans to enrol 1135 participants (actual) with primary completion expected 2029-09-18. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.
1.Cetrelimab binds its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Cetrelimab" OR ABSTRACT:"Cetrelimab" OR TITLE:"JNJ-63723283" OR ABSTRACT:"JNJ-63723283") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Cetrelimab, not a curated reading list.
Shares Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Johnson & Johnson, Bladder & urothelial cancer and the tag pipeline.
Shares Johnson & Johnson, Bladder & urothelial cancer and the tag pipeline.
Shares Johnson & Johnson, Bladder & urothelial cancer and the tag pipeline.
Shares Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Johnson & Johnson, Bladder & urothelial cancer and the tag pipeline.
Shares Johnson & Johnson, Prostate cancer and the tag pipeline.